Citi Maintained a Buy Rating on Sana Biotechnology (SANA)

Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the Best American Penny Stocks to Buy According to Analysts. On July 2, Citi analyst Samantha Semenkow maintained a Buy rating on Sana Biotechnology, Inc. (NASDAQ:SANA) with a price target of $15.

The analyst believes the company has the potential to address major market needs. One of the key factors is Sana Biotechnology, Inc.’s (NASDAQ:SANA) Type 1 Diabetes (T1D) program, which has delivered encouraging six-month data. The data shows successful graft survival and steady c-peptide production without requiring immunosuppression. The analyst noted that such consistency builds confidence in the company’s T1D asset, SC451, which could move toward an IND filing as early as 2026.

Citi Maintained a Buy Rating on Sana Biotechnology (SANA)

A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment.

Moreover, Semenkow also highlighted the company’s progress in its allogeneic CAR-T platform. She expects forthcoming data on the hypoimmune-modified CAR-T assets to provide important insights, particularly those targeting autoimmune diseases and relapsed NHL.

Sana Biotechnology, Inc. (NASDAQ:SANA) develops engineered cell-based medicines to treat diseases with unmet needs. The company’s work focuses on therapies for type 1 diabetes, autoimmune diseases, and cancer.

While we acknowledge the potential of SANA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SANA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.